* Aradigm Corp., of Hayward, Calif., received a Small Business Innovation Research grant from the National Institutes of Health for development of the company's AERx pulmonary drug delivery system for use with gene therapies targeting respiratory diseases.
* Aviron Inc., of Mountain View, Calif., said data from a Phase III study of its intranasal influenza vaccine will be unblinded in the third quarter of 1997. About 1,600 children were vaccinated with the product.
* Cel-Sci Corp., of Alexandria, Va., purchased all rights to Multikine technology from Sittonia Co. B.V., of the Netherlands. Multikine is a natural mixture of cytokines, which are immune system regulators, for treatment of HIV and cancers. The agreement gives Cel-Sci full control of Multikine, which is in clinical trials in the U.S. and Canada for prostate and head and neck cancers.
* Cypros Pharmaceutical Corp., of Carlsbad, Calif., raised $5 million in a private placement of common stock. The company said more than 90 percent of the shares were bought by Harvard University, of Cambridge, Mass.
* Cytogen Corp., of Princeton, N.J., submitted an application in Canada for approval of Quadramet, a treatment for severe pain associated with cancers that metastasize to bone. The drug is under review in the U.S. Quadramet combines the radioisotope samarium-153 with the phosphonate EDTMP to attack newly formed cancerous tissue on bone.
* Genelabs Technologies Inc., of Redwood City, Calif., said its Taiwan affiliate, Genelabs Biotechnology Ltd., will acquire a pharmaceutical manufacturing plant in Hsinchu, Taiwan, from Bristol-Myers Squibb Co., of New York. Financial terms were not disclosed. The agreement gives Genelabs manufacturing rights to 15 Bristol-Myers products in Taiwan.
* Genome Therapeutics Corp., of Waltham, Mass., and Versicor Inc., a subsidiary of Marlborough, Mass.-based Sepracor Inc., entered a collaboration to develop new anti-bacterial compounds. Financial terms were not disclosed. The two companies will share ownership of products emerging from the research.
* MedImmune Inc., of Gaithersburg, Md., said data from four Phase I trials of MEDI-493 in 38 healthy volunteers show the humanized monoclonal antibody was well-tolerated and not attacked by the participants' immune systems. The antibody is under development for respiratory syncytial virus (RSV) in children. The company said the drug was evaluated in nine Phase I and Phase I/II studies in which 300 patients have been treated. Results of the other clinical trials are expected in the next several months. MEDI-493, which has progressed to Phase III studies, is a more potent, second-generation product to MedImmune's Respigam, which already is one the market in the U.S. for RSV.
* Vertex Pharmaceuticals Inc., of Cambridge, Mass., raised another $20.5 million in connection with its recent public offering when over-allotment options were exercised by New York-based underwriters Cowen & Co.; Bear, Stearns & Co Inc.; Robertson, Stephens & Co.; and J.P. Morgan & Co. Vertex generated about $157 million in gross proceeds from the sale of 3.45 million shares at $45.50 per share. (See BioWorld Today, March 10, 1997, p. 1.)